China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
71 hedge funds and large institutions have $1.42B invested in China Biologic Products Holdings, Inc. in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 25 reducing their positions, and 10 closing their positions.
69% more call options, than puts
Call options by funds: $25M | Put options by funds: $14.8M
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
9% more capital invested
Capital invested by funds: $1.3B → $1.42B (+$118M)
3% more funds holding
Funds holding: 69 → 71 (+2)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
32% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$137M |
| 2 |
YCMGA
York Capital Management Global Advisors
New York
|
+$12.9M |
| 3 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$8.65M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.4M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
+$5.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSBC Holdings
London,
United Kingdom
|
-$30.8M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$25.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.1M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$9.78M |
| 5 |
Goldman Sachs
New York
|
-$7.57M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PM
76
Parametrica Management
Wanchai,
Hong Kong
| – | -$334K | -3,663 | Closed |
|
|
LCM
77
Laurion Capital Management
New York
| – | -$317K | -3,471 | Closed |
|
|
QT
78
Quantamental Technologies
White Plains,
New York
| – | -$308K | -3,373 | Closed |
|
|
FDCDDQ
79
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$3.65K | -40 | Closed |
|
80
BNP Paribas Financial Markets
Paris,
France
| – | -$912 | -10 | Closed |
|
CBPO Hedge Fund Activity: Q2 2019 in Review
71 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q2 2019, worth a combined $1.42B — up 9.1% from $1.3B a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CBPO positions and 10 closed out — a net gain of 2 holders — while 17 added to existing stakes and 25 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $137M. The largest seller was HSBC Holdings, cutting an estimated $30.8M.
- 71 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q2 2019, up from 69 in Q1 2019.
- Funds reported $1.42B of China Biologic Products Holdings, Inc. stock for Q2 2019, up 9.1% quarter-over-quarter.
- 12 funds opened new China Biologic Products Holdings, Inc. positions in Q2 2019 and 10 closed out, a net change of +2 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q2 2019 was Capital Research Global Investors, an estimated $137M added.
- The largest China Biologic Products Holdings, Inc. seller in Q2 2019 was HSBC Holdings, an estimated $30.8M sold.
Based on aggregated 13F filings for Q2 2019.